DE602005019694D1 - Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose - Google Patents

Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Info

Publication number
DE602005019694D1
DE602005019694D1 DE602005019694T DE602005019694T DE602005019694D1 DE 602005019694 D1 DE602005019694 D1 DE 602005019694D1 DE 602005019694 T DE602005019694 T DE 602005019694T DE 602005019694 T DE602005019694 T DE 602005019694T DE 602005019694 D1 DE602005019694 D1 DE 602005019694D1
Authority
DE
Germany
Prior art keywords
diagnosis
cancer prognosis
proliferation markers
clinical practice
new proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005019694T
Other languages
English (en)
Inventor
Genevieve Almouzni
Sophie E Polo
Stamatios E Theocharis
Philippe Vielh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Pierre et Marie Curie Paris 6, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602005019694D1 publication Critical patent/DE602005019694D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602005019694T 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose Active DE602005019694D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54811104P 2004-02-27 2004-02-27
PCT/EP2005/002578 WO2005085860A2 (en) 2004-02-27 2005-02-28 New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis

Publications (1)

Publication Number Publication Date
DE602005019694D1 true DE602005019694D1 (de) 2010-04-15

Family

ID=34919336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019694T Active DE602005019694D1 (de) 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Country Status (7)

Country Link
US (2) US7781174B2 (de)
EP (1) EP1721165B1 (de)
JP (1) JP4848355B2 (de)
AT (1) ATE459883T1 (de)
CA (1) CA2555656C (de)
DE (1) DE602005019694D1 (de)
WO (1) WO2005085860A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
CA2644468C (en) 2006-03-02 2022-02-01 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2008035692A1 (fr) * 2006-09-19 2008-03-27 Jcr Pharmaceuticals Co., Ltd. Marqueur d'identification de cellule cancéreuse et inhibiteur de prolifération de cellule cancéreuse
ES2542153T3 (es) 2007-05-30 2015-07-31 F. Hoffmann-La Roche Ag Inhibidores no nucleósidos de la transcriptasa inversa
EP2271775A4 (de) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc Biomarkergruppe zur vorhersage des wiederauftretens von kolorektalkarzinom
EP2243843A1 (de) * 2009-04-24 2010-10-27 Institut Curie HP1-Alpha als prognostischer Marker bei Krebserkrankungen des Menschen
WO2011151321A1 (en) 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
EP3304082B1 (de) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methode zur analyse einer urinprobe
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
EP3601198A4 (de) * 2017-03-30 2021-01-13 The Board of Trustees of the University of Illinois Verfahren und kit zur diagnose von bauchspeicheldrüsenkrebs in frühstadium
EP3761031A4 (de) 2018-02-28 2022-06-01 Nitto Boseki Co., Ltd. Verfahren zur isolierung von zellkernen mit erhöhter antigenizität aus immobilisierten zellen oder ffpe-gewebeabschnitten sowie antigenaktivator und kit dafür
CN111766385B (zh) * 2020-07-06 2023-09-26 河南赛诺特生物技术有限公司 术中快速鉴别肺癌和硬化性肺细胞瘤的免疫组化试剂盒
CN113984483B (zh) * 2021-09-28 2023-10-20 福建医科大学 一种冰冻切片盖玻片贴片染色方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
KR100857735B1 (ko) * 2000-11-24 2008-09-12 에자이 알앤드디 매니지먼트 가부시키가이샤 항암제에 대한 종양 세포의 감수성을 검정하는 방법
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer

Also Published As

Publication number Publication date
CA2555656A1 (en) 2005-09-15
EP1721165B1 (de) 2010-03-03
US20110003706A1 (en) 2011-01-06
US7781174B2 (en) 2010-08-24
ATE459883T1 (de) 2010-03-15
JP2007524103A (ja) 2007-08-23
EP1721165A2 (de) 2006-11-15
WO2005085860A3 (en) 2005-11-10
WO2005085860A2 (en) 2005-09-15
JP4848355B2 (ja) 2011-12-28
CA2555656C (en) 2017-03-28
US20070077577A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
EP2535716A3 (de) Krebsmarker und therapeutisches Target
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
WO2006047484A3 (en) Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
ATE479898T1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
ATE519110T1 (de) Diagnostischer nanosensor und dessen verwendung in der medizin
WO2008115518A3 (en) Biomarkers of sirtuin activity and methods of use thereof
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2008109414A3 (en) Use of endogenous fluorescence to identify invading metastatic breast tumor cells
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
DE602005024964D1 (de) Verfahren zur beurteilung der malignität einer säuger-krebszelle
MX2020002122A (es) Sustancias de control de calidad para uso con analizadores de sedimentos en orina basados en microscopia, y metodos de uso.
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
MY193895A (en) Combination test for colorectal cancer
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
WO2014146035A3 (en) Compositions and methods for cancer diagnosis
BR102015015096A2 (pt) método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
DE60309879D1 (de) Verfahren zur Diagnose von Krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition